Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 8, 2014, Pages 1806-1814

  Valencia Hipólito, Alberto ^a,b   Hernández Atenógenes, Miriam ^a   Vega, Gabriel G ^a   Maldonado Valenzuela, Altagracia ^c   Ramon, Guillermo ^d   Mayani, Héctor ^a   Peña Alonso, Yolanda ^c   Martinez Maza, Otoniel ^e   Méndez Tenorio, Alfonso ^b   Huerta Yepez, Sara ^c   Bonavida, Benjamin ^e   Vega, Mario I ^a,e  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d HOSPITAL DE PEDIATRÍA   (Mexico)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burkitt; EFS; KLF4; OS; Pediatric Burkitt lymphoma

Indexed keywords

BIOLOGICAL MARKER; KRUPPEL LIKE FACTOR 4; TUMOR MARKER; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; KRUPPEL LIKE FACTOR; PREDNISONE; VINCRISTINE;

ADOLESCENT; ARTICLE; BURKITT LYMPHOMA; BURKITT LYMPHOMA CELL LINE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; BIOLOGY; CANCER STAGING; FOLLOW UP; GENE EXPRESSION; INFANT; METABOLISM; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; TUMOR CELL LINE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; COMPUTATIONAL BIOLOGY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84904886249     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.848437     Document Type: Article

References (47)

1. Yaris N, Cakir M, Ahmetoglu A, et al. Primary Burkitt's lymphoma only involving the chest wall at relapse in a child. Leuk Lymphoma 2004; 45: 837-839.
2. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695-708.
3. Mann G, Attarbaschi A, Burkhardt B, et al. Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. Br J Haematol 2007; 139: 443-449.
4. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14: 219-228.
5. Perkins SL. Work-up and diagnosis of pediatric non-Hodgkin's lymphomas. Pediatr Dev Pathol 2000; 3: 374-390.
6. Jost P, Peschel C, Ruland J. The Bcl10/Malt1 signaling pathway as a drug target in lymphoma. Curr Drug Targets 2006; 7: 1335-1340.
7. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010; 2: a000109.
8. Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010; 21: 1486-1491.
9. Shields JM, Christy RJ, Yang VW. Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J Biol Chem 1996; 271: 20009-20017.
10. Chen ZY, Shie JL, Tseng CC. Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells. J Biol Chem 2002; 277: 46831-46839.
11. Jenkins TD, Opitz OG, Okano J, et al. Transactivation of the human keratin 4 and Epstein-Barr virus ED-L2 promoters by gut-enriched Kruppel-like factor. J Biol Chem 1998; 273: 10747-10754.
12. Katz J P, Perreault N, Goldstein B G, et al. Loss of Klf4 in mice causes altered proliferation and diff erentiation and precancerous changes in the adult stomach. Gastroenterology 2005, 128: 935-945.
13. Evans PM, Liu C. Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 554-564.
14. Wei D, Kanai M, Huang S, et al. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 2006; 27: 23-31.
15. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 2006; 6: 11-23.
16. Yu F, Li J, Chen H, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011; 30: 2161-2172.
17. Zhu X, Hart R, Chang MS, et al. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. J Immunol 2004; 173: 7141-7149.
18. van Zelm MC, van der BM, de Ridder D, et al. Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol 2005; 175: 5912-5922.
19. Chen X, Whitney EM, Gao SY, et al. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial diff erentiation. J Mol Biol 2003; 326: 665-677.
20. Guan H, Xie L, Leithauser F, et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 2010; 116: 1469-1478.
21. Kharas MG, Yusuf I, Scarfone VM, et al. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood 2007; 109: 747-755.
22. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximabmediated cell signaling and chemo/immuno-sensitization of drugresistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009; 15: 6582-6594.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
24. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
25. Basso K, Margolin AA, Stolovitzky G, et al. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37: 382-390.
26. Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immuneprivileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
27. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259-7264.
28. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
29. Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22: 1917-1924.
30. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in populationbased prospective clinical trials. Blood 2008; 112: 1374-1381.
31. Lecane PS, Karaman MW, Sirisawad M, et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005; 65: 11676-11688.
32. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-8232.
33. Foster KW, Frost AR, McKie-Bell P, et al. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000; 60: 6488-6495
34. Huang CC, Liu Z, Li X, et al. KLF4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia. Cancer Biol Ther 2005; 4: 1401-1408.
35. Klaewsongkram J, Yang Y, Golech S, et al. Kruppel-like factor 4 regulates B cell number and activation-induced B cell proliferation. J Immunol 2007; 179: 4679-4684.
36. Cairo M S, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
37. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non- Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
38. Aldoss I T, Weisenburger D D, Fu K, et al. Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park) 2008; 22: 1508-1517.
39. Buckley AF, Kuo CT, Leiden JM. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat Immunol 2001; 2: 698-704.
40. Yusuf I, Kharas MG, Chen J, et al. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol 2008; 20: 671-681.
41. Klm J, C hu J, S hen X, et al. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132: 1049-1061.
42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 633-676.
43. Castellano G, Torrisi E, Ligresti G, et al. Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle 2010; 9: 557-563.
44. Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109: 3922-3928.
45. Camacho-Vanegas O, Till J, Miranda-Lorenzo I, et al. Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors. FASEB J 2013; 27: 432-436.
46. Okuda H, Xing F, Pandey PR, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res 2013; 73: 1434-1444.
47. Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009; 106: 8912-8917.